Published in Circ Res on November 25, 2009
A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. Circ Res (2010) 3.00
Adiponectin and cardiovascular health: an update. Br J Pharmacol (2012) 1.42
Globular adiponectin, acting via AdipoR1/APPL1, protects H9c2 cells from hypoxia/reoxygenation-induced apoptosis. PLoS One (2011) 1.13
Role of adiponectin in metabolic and cardiovascular disease. J Exerc Rehabil (2014) 1.07
The role of adipose tissue in mediating the beneficial effects of dietary fish oil. J Nutr Biochem (2010) 1.02
Obesity and pulmonary arterial hypertension: Is adiponectin the molecular link between these conditions? Pulm Circ (2012) 0.96
Adiponectin action: a combination of endocrine and autocrine/paracrine effects. Front Endocrinol (Lausanne) (2011) 0.95
Sevoflurane preconditioning attenuates myocardial ischemia/reperfusion injury via caveolin-3-dependent cyclooxygenase-2 inhibition. Circulation (2013) 0.92
Hypoadiponectinaemia in diabetes mellitus type 2: molecular mechanisms and clinical significance. Clin Exp Pharmacol Physiol (2011) 0.89
Regulation of Abro1/KIAA0157 during myocardial infarction and cell death reveals a novel cardioprotective mechanism for Lys63-specific deubiquitination. J Mol Cell Cardiol (2010) 0.88
Adiponectin as a potential biomarker of vascular disease. Vasc Health Risk Manag (2015) 0.87
Tongxinluo Improves Cardiac Function and Ameliorates Ventricular Remodeling in Mice Model of Myocardial Infarction through Enhancing Angiogenesis. Evid Based Complement Alternat Med (2013) 0.85
PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression. PLoS One (2013) 0.83
PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system? World J Cardiol (2011) 0.82
N-3 Polyunsaturated Fatty Acids and Inflammation in Obesity: Local Effect and Systemic Benefit. Biomed Res Int (2015) 0.82
Pleiotropic effects of glitazones: a double edge sword? Front Pharmacol (2011) 0.81
Globular adiponectin protects H9c2 cells from palmitate-induced apoptosis via Akt and ERK1/2 signaling pathways. Lipids Health Dis (2012) 0.79
Adiponectin fine-tuning of liver regeneration dynamics revealed through cellular network modelling. J Physiol (2015) 0.79
Fish oil decreases inflammation and reduces cardiac remodeling in rosiglitazone treated aging mice. Pharmacol Res (2010) 0.78
PPARs: Protectors or Opponents of Myocardial Function? PPAR Res (2015) 0.77
Fish oil N-3 fatty acids increase adiponectin and decrease leptin levels in patients with systemic lupus erythematosus. Mar Drugs (2015) 0.75
2,3,5,4'-Tetrahydroxystilbene-2-O-β-D-glucoside protects murine hearts against ischemia/reperfusion injury by activating Notch1/Hes1 signaling and attenuating endoplasmic reticulum stress. Acta Pharmacol Sin (2017) 0.75
Short-Term Therapy with Rosiglitazone, a PPAR-γ Agonist, Improves Metabolic Profile and Vascular Function in Nonobese Lean Wistar Rats. ISRN Pharmacol (2012) 0.75
Caveolin-3 plays a critical role in autophagy after ischemia-reperfusion. Am J Physiol Cell Physiol (2016) 0.75
Suppression of oxidative stress in endothelial progenitor cells promotes angiogenesis and improves cardiac function following myocardial infarction in diabetic mice. Exp Ther Med (2016) 0.75
The evolving role of adiponectin as an additive biomarker in HFrEF. Heart Fail Rev (2016) 0.75
Metformin in combination with rosiglitazone contribute to the increased serum adiponectin levels in people with type 2 diabetes mellitus. Exp Ther Med (2017) 0.75
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol (2000) 9.85
Plasma adiponectin levels and risk of myocardial infarction in men. JAMA (2004) 7.46
Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med (2005) 6.04
PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes (2001) 5.18
Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest (2000) 5.07
Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA (2007) 5.02
Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol (2003) 4.86
ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab (2002) 4.64
Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem (2005) 4.32
Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol (2003) 3.89
Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev (2007) 3.19
Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res (2000) 3.02
Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology (2002) 2.72
Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation (2008) 2.64
Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation (2002) 2.57
Increased beta -oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem (2002) 2.33
Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation (2007) 2.28
Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol (2004) 2.00
Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol (2001) 1.78
Cardioprotective effects of thioredoxin in myocardial ischemia and reperfusion: role of S-nitrosation [corrected]. Proc Natl Acad Sci U S A (2004) 1.76
Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J (2002) 1.73
Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J Mol Cell Cardiol (2007) 1.55
Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling. J Cell Physiol (2002) 1.47
Myocardial infarction in diabetic rats: role of hyperglycaemia on infarct size and early expression of hypoxia-inducible factor 1. Diabetologia (2002) 1.38
Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids. Am J Physiol Endocrinol Metab (2008) 1.33
Acute myocardial infarction in dogs with experimental diabetes. Cardiovasc Res (1993) 1.28
The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart (2003) 1.24
Pharmacokinetics of the potent redox-modulating manganese porphyrin, MnTE-2-PyP(5+), in plasma and major organs of B6C3F1 mice. Free Radic Biol Med (2008) 1.24
Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res (2004) 1.16
Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists. Diabetes (2002) 1.16
Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation (2003) 1.15
Thiazolidinediones: do harms outweigh benefits? CMAJ (2008) 1.09
Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice. Biomed Pharmacother (2007) 1.06
Diabetes mellitus and heart failure. Congest Heart Fail (2003) 0.97
Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production. Arterioscler Thromb Vasc Biol (2007) 0.97
Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease. Diab Vasc Dis Res (2008) 0.92
Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. J Intern Med (2007) 0.90
Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism (2005) 0.90
Different effect of acute treatment with rosiglitazone on rat myocardial ischemia/reperfusion injury by administration method. Eur J Pharmacol (2008) 0.84
Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus. Diabet Med (2008) 0.79
Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis (2004) 6.83
T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation (2007) 6.23
Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol (2002) 6.20
Seven-transmembrane-spanning receptors and heart function. Nature (2002) 5.38
Reversal of obesity by targeted ablation of adipose tissue. Nat Med (2004) 4.23
A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med (2008) 3.98
A guide to analysis of mouse energy metabolism. Nat Methods (2011) 3.82
Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest (2006) 3.44
NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice. Nat Med (2003) 3.26
Absence of the SRC-2 coactivator results in a glycogenopathy resembling Von Gierke's disease. Science (2008) 3.17
Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation (2002) 3.15
Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. Cell Metab (2006) 3.14
Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest (2008) 3.11
A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. Circ Res (2010) 3.00
The dragon strikes: lessons from the Wenchuan earthquake. Anesth Analg (2010) 2.78
Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J (2008) 2.78
Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. Cell (2007) 2.65
Protection against fatty liver but normal adipogenesis in mice lacking adipose differentiation-related protein. Mol Cell Biol (2006) 2.63
TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop. Nat Cell Biol (2013) 2.62
Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liver. Hepatology (2007) 2.53
Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med (2007) 2.48
Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology (2010) 2.47
C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation (2004) 2.43
Increased beta -oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem (2002) 2.33
A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest (2003) 2.32
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res (2012) 2.31
Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur Heart J (2005) 2.29
Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation (2007) 2.28
Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J Immunol (2003) 2.23
G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res (2008) 2.22
Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation (2008) 2.17
Hyperphosphorylation of the cardiac ryanodine receptor at serine 2808 is not involved in cardiac dysfunction after myocardial infarction. Circ Res (2012) 2.16
Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation (2002) 2.14
Differential gene expression and genomic patient stratification following left ventricular assist device support. J Am Coll Cardiol (2003) 2.08
Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and beta-adrenergic signaling. Circ Res (2006) 2.08
Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest (2007) 2.03
Absence of p21Waf1/Cip1/Sdi1 modulates macrophage differentiation and inflammatory response and protects against atherosclerosis. Circulation (2004) 2.00
Neurogenin3 is sufficient for transdetermination of hepatic progenitor cells into neo-islets in vivo but not transdifferentiation of hepatocytes. Dev Cell (2009) 2.00
Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearance. Circ Res (2006) 1.95
Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci U S A (2008) 1.93
C1q/tumor necrosis factor-related protein-3, a newly identified adipokine, is a novel antiapoptotic, proangiogenic, and cardioprotective molecule in the ischemic mouse heart. Circulation (2012) 1.90
Cellular energy depletion resets whole-body energy by promoting coactivator-mediated dietary fuel absorption. Cell Metab (2011) 1.89
The orphan nuclear receptor SHP regulates PGC-1alpha expression and energy production in brown adipocytes. Cell Metab (2005) 1.89
Negative impact of β-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms. Hypertension (2013) 1.83
A role for lipid bodies in the cross-presentation of phagocytosed antigens by MHC class I in dendritic cells. Immunity (2009) 1.82
Targeted inactivation of MLL3 histone H3-Lys-4 methyltransferase activity in the mouse reveals vital roles for MLL3 in adipogenesis. Proc Natl Acad Sci U S A (2008) 1.80
Gene therapy in heart failure. Circ Res (2008) 1.79
Adiponectin deficiency promotes endothelial activation and profoundly exacerbates sepsis-related mortality. Am J Physiol Endocrinol Metab (2008) 1.79
Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med (2008) 1.78
Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. Proc Natl Acad Sci U S A (2009) 1.77
Cardioprotective effects of thioredoxin in myocardial ischemia and reperfusion: role of S-nitrosation [corrected]. Proc Natl Acad Sci U S A (2004) 1.76
Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc Natl Acad Sci U S A (2003) 1.74
A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med (2011) 1.74
Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation (2006) 1.73
Biology of intracranial aneurysms: role of inflammation. J Cereb Blood Flow Metab (2012) 1.73
Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation (2007) 1.73
Genetic deficiency of adiponectin protects against acute kidney injury. Kidney Int (2013) 1.71
Metabolic adaptations in the absence of perilipin: increased beta-oxidation and decreased hepatic glucose production associated with peripheral insulin resistance but normal glucose tolerance in perilipin-null mice. J Biol Chem (2004) 1.69
S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes. J Am Coll Cardiol (2011) 1.68
Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet (2002) 1.67
Extrapancreatic insulin-producing cells in multiple organs in diabetes. Proc Natl Acad Sci U S A (2004) 1.67
β-Adrenergic regulation of cardiac progenitor cell death versus survival and proliferation. Circ Res (2012) 1.66
AMP-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/antinitrative protection of adiponectin. Circulation (2009) 1.65
Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex. J Biol Chem (2006) 1.64
Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation (2006) 1.64
Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res (2013) 1.62
Glucose-dependent transcriptional regulation by an evolutionarily conserved glucose-sensing module. Diabetes (2006) 1.61
β-arrestin1-biased β1-adrenergic receptor signaling regulates microRNA processing. Circ Res (2013) 1.59
Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest (2004) 1.58
Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ Res (2005) 1.57
Targeted inhibition of cardiomyocyte Gi signaling enhances susceptibility to apoptotic cell death in response to ischemic stress. Circulation (2008) 1.56
Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heart. Sci Transl Med (2013) 1.55
Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med (2011) 1.54
Functional compensation for adipose differentiation-related protein (ADFP) by Tip47 in an ADFP null embryonic cell line. J Biol Chem (2006) 1.53
Level of G protein-coupled receptor kinase-2 determines myocardial ischemia/reperfusion injury via pro- and anti-apoptotic mechanisms. Circ Res (2010) 1.52
Cardiac G-protein-coupled receptor kinase 2 ablation induces a novel Ca2+ handling phenotype resistant to adverse alterations and remodeling after myocardial infarction. Circulation (2012) 1.52
Direct evidence of intracrine angiotensin II signaling in neurons. Am J Physiol Cell Physiol (2014) 1.51
Downregulation of adiponectin induced by tumor necrosis factor α is involved in the aggravation of posttraumatic myocardial ischemia/reperfusion injury. Crit Care Med (2011) 1.50
Dickkopf-3 attenuates pressure overload-induced cardiac remodelling. Cardiovasc Res (2014) 1.49
Deficiency of adipose differentiation-related protein impairs foam cell formation and protects against atherosclerosis. Circ Res (2008) 1.48
Triage during the week of the Sichuan earthquake: a review of utilized patient triage, care, and disposition procedures. Injury (2010) 1.46